Experienced in Common Variable Immune Deficiency

Theodoros P. Vassilakopoulos

Athens, ESYE31, GR 
Experienced in Common Variable Immune Deficiency
Athens, ESYE31, GR 
OverviewLocationsClinical Research

Overview

Theodoros Vassilakopoulos practices in Athens, Greece. Mr. Vassilakopoulos is rated as an Experienced expert by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Hodgkin Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 225 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Common Variable Immune Deficiency.

Gender
Male

Locations

Athens, ESYE31, Greece
Other Locations
Evangelismos, ESYE43, Greece
Simos, ESYE23, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 2

225 Total Publications

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: October 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vassilakopoulos's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 50 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile